VA as Maintenance Therapy Post Allo-HSCT in MDS and AML

Sponsor
Navy General Hospital, Beijing
Study ID
NCT06598384
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax combined with Azacytidine — DRUG
    Patients were treated by venetoclax and azacytidine: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5.

Study Details

The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Key Dates

Start date
Sep 30, 2024
Status verified
Sep 2024
Primary completion
Sep 30, 2030
Completion
Sep 30, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Venetoclax combined with Azacytidine
    Patients were treated by venetoclax and azacytidine

Primary Outcome Measure

Relapse Rate [ Time Frame: 1 year ]

Central Contacts

Related Studies